

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6835793

|   |                                  |
|---|----------------------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                   |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                       |
| <b>CONVEYING PARTY DATA</b>   |                                  |
| <b>Name</b>   | <b>Execution Date</b>            |
| JANSSEN VACCINES & PREVENTION B.V.  | 04/26/2021                       |
| <b>RECEIVING PARTY DATA</b>   |                                  |
| <b>Name:</b>  | JANSSEN PHARMACEUTICALS, INC.    |
| <b>Street Address:</b>  | 1125 TRENTON-HARBOURTON ROAD     |
| <b>City:</b>  | TITUSVILLE                       |
| <b>State/Country:</b>   | NEW JERSEY                       |
| <b>Postal Code:</b>   | 08560                            |
| <b>PROPERTY NUMBERS Total: 1</b>  |                                  |
| <b>Property Type</b>  | <b>Number</b>                    |
| <b>Application Number:</b>  | 17387105                         |
| <b>CORRESPONDENCE DATA</b>  |                                  |
| <b>Fax Number:</b>  | (215)446-8135                    |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                  |
| <b>Phone:</b>   | 2154468134                       |
| <b>Email:</b>   | adel.drake@icemiller.com         |
| <b>Correspondent Name:</b>  | ADEL DRAKE                       |
| <b>Address Line 1:</b>  | 1735 MARKET STREET               |
| <b>Address Line 2:</b>  | SUITE 3450                       |
| <b>Address Line 4:</b>  | PHILADELPHIA, PENNSYLVANIA 19103 |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 004852.11805/161US17             |
| <b>NAME OF SUBMITTER:</b>   | ANDREW P. BARANIAK, PH.D.        |
| <b>SIGNATURE:</b>   | /Andrew P. Baraniak, Ph.D./      |
| <b>DATE SIGNED:</b>   | 07/28/2021                       |
| <b>Total Attachments: 2</b>   |                                  |
| source=Executed Intercompany Assignment- JVP-JPI recorded 7-28-21#page1.tif   |                                  |
| source=Executed Intercompany Assignment- JVP-JPI recorded 7-28-21#page2.tif   |                                  |

**General Assignment**

WHEREAS, **JANSSEN VACCINES & PREVENTION B.V.** having its place of business at Archimedesweg 4, 2333 CN Leiden, THE NETHERLANDS (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

**COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING  
CORONAVIRUS INFECTION - SARS-COV-2 VACCINES**

as described in the following patent applications:

- PCT/US2021/015946 with filing date 30 January 2021
- US 17/163,357 with filing date 30 January 2021
- Argentina P210100259 with filing date 30 January 2021
- Taiwan 110103610 with filing date 30 January 2021
- Lebanon 12117 with filing date 25 February 2021
- Pakistan 103/2021 with filing date 01 February 2021
- Uruguay 99.060 with filing date 01 February 2021

WHEREAS, **JANSSEN PHARMACEUTICALS, INC.** a Corporation having an address of 1125 Trenton-Harbourton Rd., Titusville, NJ 08560, US (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,


NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority from said patent applications, in and to all said inventions disclosed in said patent applications and in and to said patent applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

Assignor and Assignee hereby agree that this Assignment is expressly made NUNC PRO TUNC to have the same legal force and effect as if executed on 30 January 2021.

IN TESTIMONY WHEREOF, the Assignor set hereunto its hand and seal this date.


**FOR JANSSEN VACCINES & PREVENTION B.V.**

  
\_\_\_\_\_  
Maarten E. Santman  
Legal Director & Corporate Secretary

Date: 26 April 2021

IN TESTIMONY WHEREOF, the Assignee set hereunto its hand and seal this date.

**FOR JANSSEN PHARMACEUTICALS, INC.**

  
\_\_\_\_\_  
Eva van Wanroij  
Authorized Signatory

Date: 26 April 2021